MT1L: A Non-Coding RNA Molecule as A Potential Drug Target for Cancer

Target Name: MT1L

NCBI ID: G4500

MT1L

Other Name(s): MTF | MT1R | MT1 | Metallothionein 1L, pseudogene | metallothionein 1L, pseudogene

MT1L: A Non-Coding RNA Molecule as A Potential Drug Target for Cancer

MT1L, or microRNA-181, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for a variety of diseases, including cancer. MT1L is a key regulator of stem cell proliferation and has been shown to play a role in the development and progression of many diseases, including cancer.

MT1L is a small molecule that is expressed in many different tissues and cells in the body. It is typically expressed in high levels in cancer cells and has been shown to be downregulated in many tissues and cells that are normal. This downregulation of MT1L has been shown to promote the growth and survival of cancer cells, making it a promising target for cancer treatments.

One of the key mechanisms by which MT1L promotes cancer cell growth and survival is by regulating the expression of genes that are involved in cell growth and division. MT1L has been shown to interact with several key genes that are involved in cell growth and development, including the TGF-β pathway. TGF-β is a well-known signaling pathway that is involved in the regulation of cell growth, differentiation, and survival. MT1L has been shown to play a role in the regulation of TGF-β signaling by targets such as the Smad6 gene.

Another mechanism by which MT1L promotes cancer cell growth and survival is by regulating the expression of genes that are involved in cell survival. MT1L has been shown to interact with several key genes that are involved in cell survival, including the BCL-2 gene. BCL-2 is a well-known gene that is involved in the regulation of cell survival and has been implicated in the development of many diseases, including cancer. MT1L has been shown to play a role in the regulation of BCL-2 signaling by targets such as the p53 gene.

In addition to its role in promoting cancer cell growth and survival, MT1L is also involved in the regulation of stem cell proliferation. MT1L has been shown to play a role in the regulation of stem cell self-renewal and has been shown to play a role in the development of cancer stem cells. This suggests that MT1L may be a useful target for cancer stem cell therapies.

MT1L has also been shown to play a role in the regulation of tissue repair and regeneration. MT1L has been shown to interact with several key genes that are involved in tissue repair and regeneration, including the FGF1 gene. FGF1 is a well-known gene that is involved in the regulation of tissue repair and regeneration and has been implicated in the development of many diseases, including cancer. MT1L has been shown to play a role in the regulation of FGF1 signaling by targets such as the Fgfr1 gene.

In conclusion, MT1L is a small molecule that has been shown to play a role in the regulation of stem cell proliferation, cancer cell growth and survival, and tissue repair and regeneration. These properties make MT1L a promising target for cancer treatments. Further research is needed to fully understand the mechanisms by which MT1L promotes cancer growth and survival, and to develop effective therapies that target MT1L.

Protein Name: Metallothionein 1L, Pseudogene

Functions: Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids

The "MT1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MT1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets